218 related articles for article (PubMed ID: 19735093)
1. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
[TBL] [Abstract][Full Text] [Related]
2. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
3. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques.
Simón-Sánchez J; Martí-Massó JF; Sánchez-Mut JV; Paisán-Ruiz C; Martínez-Gil A; Ruiz-Martínez J; Sáenz A; Singleton AB; López de Munain A; Pérez-Tur J
Mov Disord; 2006 Nov; 21(11):1954-9. PubMed ID: 16991141
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
6. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).
Ruiz-Martínez J; Gorostidi A; Ibañez B; Alzualde A; Otaegui D; Moreno F; López de Munain A; Bergareche A; Gómez-Esteban JC; Martí Massó JF
Mov Disord; 2010 Oct; 25(14):2340-5. PubMed ID: 20721916
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pathological characterization of Lrrk2.
Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 R1441G in Spanish patients with Parkinson's disease.
Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
[TBL] [Abstract][Full Text] [Related]
10. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
[TBL] [Abstract][Full Text] [Related]
11. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
12. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
Taylor JP; Mata IF; Farrer MJ
Trends Mol Med; 2006 Feb; 12(2):76-82. PubMed ID: 16406842
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
[TBL] [Abstract][Full Text] [Related]
14. First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.
Puschmann A; Englund E; Ross OA; Vilariño-Güell C; Lincoln SJ; Kachergus JM; Cobb SA; Törnqvist AL; Rehncrona S; Widner H; Wszolek ZK; Farrer MJ; Nilsson C
Parkinsonism Relat Disord; 2012 May; 18(4):332-8. PubMed ID: 22154298
[TBL] [Abstract][Full Text] [Related]
15. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
16. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
[TBL] [Abstract][Full Text] [Related]
17. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
[TBL] [Abstract][Full Text] [Related]
18. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
[TBL] [Abstract][Full Text] [Related]
20. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease.
Golub Y; Berg D; Calne DB; Pfeiffer RF; Uitti RJ; Stoessl AJ; Wszolek ZK; Farrer MJ; Mueller JC; Gasser T; Fuchs J
Parkinsonism Relat Disord; 2009 Aug; 15(7):539-41. PubMed ID: 19041274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
